The morphology of myeloma cells changes with the progression of the disease

Introduction

Multiple myeloma is the most common and most clinically significant disease in the group of plasma cell dyscrasias. This represents about 1.5% of all cancers and about 12% of haematological neoplasia. According to the Polish Myeloma Group, it is estimated that in Poland there are about 1500 cases per year [1].

The treatment of multiple myeloma in the last decade has seen revolutionary change. Before the era of alkylating agents, patients died within the first year. The use of melphalan in the 1960s resulted in improved survival. Another important advance was made in the 1980s, when high-dose chemotherapy and autologous haematopoietic stem cell transplantation were introduced. New drugs such as thalidomide, lenalidomide and bortezomib fundamentally changed the way we treat patients with multiple myeloma. The overall survival of patients in the last decade has improved significantly from 30 months to 45 months [2, 3].

The clinical course of multiple myeloma in individual patients may differ significantly. In chemosensitive disease, patients require intermittent treatment and the use of new forms of therapy can sometimes achieve 10-year survival. The aggressive form of the disease rapidly develops resistance, and patients do not survive one year [4].

This heterogeneity is reflected in the morphology of plasma cells. Multiple myeloma shows extremely high variability in this area. We decided to make a detailed analysis of the morphological characteristics of plasma cells in newly diagnosed myeloma patients, and in the same patients during relapse.

Material and methods

This retrospective study included 103 MM patients, treated with chemotherapy between March 1996 and June 2011 (in a single institution). Median age at diagnosis was 61 years (25–86). The M/F ratio was 1.3. In the study group myeloma isotypes were identified as follows: IgG 69 patients, IgA 20 pa­tients, light chain disease 10 patients, non-secretory multiple myeloma 2 patients, IgD one patient, IgM one patient. Clinical staging was based on Durie-Salmon criteria: 23 patients with stage I, 33 patients with stage II, 47 patients with stage III. Conventional chemotherapy was used in 96 patients. High-dose chemotherapy was used in 7 patients.

Quantitative and qualitative analyses of neoplastic infiltration were based on cytological evaluation of bone marrow smears. Aspiration biopsies were performed by puncturing the sternum or iliac crest. Smears were stained typically with May Grunwald and Giemsa. Preparations had to meet the following conditions:

• satisfactory marrow cellularity;

• percentage of plasma cells at least 10%;

• high-quality staining for the identification of cell types.

For each patient bone marrow cytological preparations obtained from two punctures were evaluated. The first bone marrow biopsy was performed before treatment, at the time of diagnosis. The second bone marrow biopsy was performed at the time of relapse. The interval between these cytological examinations was on average 26 months.

Assessment of morphological and morphometric measurements of myeloma cells was performed using a digital cell imaging system (Olympus). Bone marrow smears were subjected to a three-step evaluation:

First step: Assessment of marrow cellularity in the 40 lens. The smears were reliable with uniform distribution of cells in the viewing field.

Second step: Evaluation of myeloma infiltration was made sequentially counting 500 haematopoietic cells in the 100 lens.

Third step: Evaluation of qualitative changes in myeloma infiltration was made sequentially counting 100 plasma cells in the 100 lens.

The morphological features and morphometric parameters of myeloma cells are shown in Table 1.

Assessment of morphological types of myeloma was based on classifications Goasguen and Greipp [5, 6].



Statistical analysis



For statistical analysis the following were used: Kruskal-Wallis test, Mann-Whitney U-test, Wilcoxon test for nonparametric data, Student's t-test for parametric data.

Results

We found that progression of multiple myeloma was reflected in the alterations of morphology of myeloma cells. The observed differences in some morphological features and morphometric parameters were statistically significant (Table 2).

In recurrent disease myeloma cells are larger, have a larger circuit and increased anisocytosis, increased nucleus surface area and higher nuclear-cytoplasmic ratio. The described changes indicate an increased rate of atypia and cancer malignancy which is usually reflected in the clinical course. In recurrent disease giant plasma cells and flaming cells are more common. In the cytoplasm of myeloma cells the number of vacuoles and Snapper-Schneid granules increases.

We evaluated in detail an important prognostic parameter which is the presence of plasma cells with irregular nuclei (PCIN). Earlier studies have shown that PCIN  5% of marrow plasma cells are a strong, 2-microglobulin-independent, unfavourable prognostic factor (Fig. 1).

Seventeen patients with PCIN  5% with newly diagnosed multiple myeloma were identified. 25 patients with PCIN

 5% with recurrent disease were identified. Only one patient had lost this morphological feature during treatment.

We analysed the cell morphology in various periods of disease progression. In clinically advanced disease (period III) plasma cells were larger, with more nucleoli and higher nuclear-cytoplasmic ratio.

In the last step we performed a morphological classification of myeloma patients. Two systems, Greipp and Goasguen, were used. We found that with the biological course of the disease, in some patients there is a change in morphological type of multiple myeloma. We found that the change was noted in 26 patients according to Greipp criteria and in

21 patients according to Goasguen criteria. In most cases change in the morphological type was related to the appearance of a cell clone with a lower degree of maturity (Table 3).

Discussion

Multiple myeloma according to the WHO classification is separated as a distinct disease entity. However, various prognostic factors and results of clinical trials indicate the heterogeneity of the population of patients with this malignancy. Chromosome aberrations discovered in recent years have allowed haematologists to differentiate various groups of patients with significantly different prognosis [7, 8]. Now the question is whether this discrepancy demonstrated by clinical-laboratory tests and cytogenetic studies is associated with polymorphism of myeloma cells viewed under a light microscope [9].

In the available literature we did not find publications that in such detail discussed the morphology of myeloma cells and made assessment at various periods of the disease.

Here we found that in relapsed multiple myeloma, plasma cells are larger, have a larger nucleus and higher nuclear-cytoplasmic ratio, and the anisocytosis is more severe. These features of cell atypia are more pronounced in patients with clinically advanced disease (period III Du­rie--Salmon). Loss of oval shape of the nucleus is a cytological criterion of malignancy in solid tumours. In multiple myeloma, this feature has already been studied in the 1990s and has been recognized as a strong, poor prognostic factor. Most authors recognize that plasma cells with irregular nuclei significantly affect the prognosis when present in an amount of at least 5% of myeloma cells [10, 11].

Leleu studied 169 patients with newly diagnosed multiple myeloma and 48 patients in relapse. Plasma cells with irregular nuclei  5% was found in 35/169 newly diagnosed patients (20.7%). Plasma cells with irregular nuclei  5% was found in 15/48 relapsed patients (31%). Similar results were obtained by Zandecki. PCIN  5% was found in 34/193 newly diagnosed patients (17.5%). Plasma cells with irregular nuclei  5% was found in 19/47 relapsed patients (40%). Both Leleu and Zandecki showed that all patients with PCIN  5% before treatment maintained this feature during relapse.

Cytogenetic studies have shown the relationship between the frequency of plasma cells with irregular nuclei and hypoploidy. Hypoploidy was found in 52% of patients with PCIN  5% and 21% of patients with PCIN < 5%.

The authors demonstrated significantly different median survival between patients with PCIN  5% and with PCIN < 5%: 21 months vs. 41 months. Occurrence of PCIN was not correlated with serum β2-microglobulin [10, 11].

In our study, plasma cells with irregular nuclei, regardless of their percentage, were observed in about half of patients, 50/103 (48%). A similar result was reported by Leleu. Before treatment we found PCIN  5% in 17/103 patients (17%). In recurrent disease we found PCIN  5% in 25/103 patients (24%). 16 patients with PCIN  5% with newly diagnosed multiple myeloma maintained this morphological feature despite cytostatic treatment. PCIN incidence was not related to the number of treatment lines, type of treatment (conventional vs. high-dose) or renal function. Furthermore, we found differences in the incidence of PCIN depending on the isotype of monoclonal protein: 5/20 (25%) patients with IgA myeloma vs. 10/69 (14%) patients with IgG myeloma. It seems that it may be responsible for a more aggressive course of disease in patients with IgA myeloma, which is indicated by some authors.

Plasma cells with irregular nuclei are a strong, 2-micro­globulin-independent, unfavourable prognostic factor. Assessment of this morphological feature is simple and can be used in clinical practice. PCIN  5% are observed only during the proliferative process. In monoclonal gammopathy of undetermined significance PCIN never exceed 5%. It appears that PCIN level correlates with an intrinsic factor determining malignancy, rather than a tumour mass [10, 11].

Many studies have confirmed the relationship between the morphology of myeloma cells and the course of disease. Various morphological classifications have been proposed describing the relationship between cell morphology and prognosis. Clinical studies have confirmed that poor prognosis is associated with the occurrence of morphological changes in the nucleus: nuclei size, nuclei shape, number of nucleoli [12, 13]. In 1948 Byard reported that none of ten patients with plasmablastic multiple myeloma survived one year. The plasmablastic type was later identified as a strong, independent, unfavourable factor [6, 14].

In our study, we needed two morphological classifications of multiple myeloma. Plasmablastic type (according to Greipp criteria) and type III (according to Goasguen criteria) were significantly more frequent in recurrent disease.

In conclusion,the variability of morphological forms of myeloma cells may be due to their unique ability to produce antibodies. A collection of immunoglobulins affects the abundance of cytoplasm, changing its structure and staining. Secretory failure results in the formation of vacuoles and various size inclusion bodies. Changes in the cell nucleus – size increase, shape irregularity, diffuse chromatin structure and the presence of nucleoli – are markers of malignancy. In our view changes in the morphology of myeloma cells arise from the natural, progressive course of the disease rather than the applied treatment.



The authors declare no conflict of interest.

References

 1. Dmoszyńska A, Kraj M, Walter-Croneck A. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznania i leczenia szpiczaka plazmocytowego. Acta Haematol Pol 2009: 753-82.

 2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20.

 3. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-110.

 4. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 2011; 25: 107-12.

 5. Goasguen JE, Zandecki M, Mathiot C, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res 1999; 23: 1133-40.

 6. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305-10.

 7. Mahindra A, Hideshima T, Anderson K. Multiple myeloma: biology of the disease. Blood Rev. 2010; 24 Suppl 1: S5-11.

 8. Sawyer J. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genetics 2011; 204: 3-12.

 9. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmocytoid and immature morphology, respectively, in multiple myeloma. Leuk 2003; 17: 2032-45.

10. Leleu X, Genevieve F, Guieze R, et al. Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. Leuk Res 2005; 29: 665-71.

11. Zandecki M, Prat-Lesaffre S, Gevevieve F. Plasma cells with an irregular nucleus define a morphologic subgroup of adverse prognosis in multiple myeloma. Haematologica 1999; 84 (EHA-4 Abstract Book): 29.

12. Goasguen J, Mathiot C, Zandecki M. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Blood 1994; 84: 654a.

13. Murakami H, Nemoto K, Sawamura M, et al. Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol 1992; 87: 113-7.

14. Rajkumar V, Fonseca R, Lacy M, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol 1999; 17: 1551-7.



Address for correspondence



Jarosław Wajs

Lebiodowa 17L/4

04-674 Warszawa

tel. 508 094 318

email: jarek.hem@gmail.com



Submitted: 3.10.2012

Accepted: 7.11.2012